fluorodeoxyglucose f18 has been researched along with quinazolines in 53 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (15.09) | 29.6817 |
| 2010's | 45 (84.91) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Ebi, H; Kawada, K; Kojima, Y; Minami, H; Mukai, H; Murakami, K; Sato, T; Shimokata, K; Tahara, M | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Aboagye, EO; Aibgirhio, FI; Forster, M; Golovko, O; Jackman, AL; Leyton, J; Mitchell, F; Perumal, M; Pillai, RG | 1 |
| Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH | 1 |
| Allal, BC; Brillouet, S; Canal, P; Caselles, O; Courbon, F; Delord, JP; Filleron, T; Rochaix, P; Thomas, F; Vergez, S | 1 |
| Aukema, TS; Codrington, HE; Kappers, I; Klomp, HM; Olmos, RA; van Pel, R; van Tinteren, H | 1 |
| Binns, DS; Callahan, J; Conti, P; Fine, BM; Hicks, RJ; Macfarlane, D; Mileshkin, L; Pirzkall, A; Scott, AM; Yu, W | 1 |
| Alauddin, MM; Balatoni, J; Flores, L; Gelovani, JG; Gonzalez-Lepera, C; Krasnykh, V; Mukhapadhyay, U; Najjar, AM; Ogawa, K; Pal, A; Shavrin, A; Soghomonyan, S; Tong, W; Volgin, AY; Yeh, HH; Young, D | 1 |
| Benz, MR; Bockisch, A; Czernin, J; Damoiseaux, RD; Hartung, V; Hildebrandt, IJ; Laing, RE; Phelps, ME; Walter, MA; Weber, WA | 1 |
| Banerjee, D; Bertino, JR; Blasberg, RG; Cai, S; de Stanchina, E; Kochetkov, T; Moroz, MA; Nair, J; Schwartz, GK; Serganova, I; Shamis, M; Wu, J | 1 |
| Amler, LC; Charu, V; Fine, BM; Gitlitz, BJ; Hicks, RJ; Hughes, BG; Macfarlane, D; Mileshkin, L; Mitchell, PL; Pirzkall, A; Solomon, B; Yu, W | 1 |
| Boellaard, R; Buettner, R; Dietlein, M; Draube, A; Engel-Riedel, W; Hallek, M; Hellmich, M; Heukamp, L; Jacobs, AH; Ko, YD; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Schlesinger, A; Schulte, K; Smit, E; Stoelben, E; Thomas, RK; Toepelt, K; Ullrich, RT; Wolf, J; Zander, T | 1 |
| Colomer, R; Quintela-Fandino, M | 1 |
| Eshuis, SA; Gemmel, F; Gemmel, P; van Vollenhoven, F | 1 |
| Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M | 1 |
| Allen-Auerbach, MS; Benz, MR; Czernin, J; Figlin, R; Garon, EB; Herrmann, K; Phelps, ME; Reckamp, KL; Walter, F; Weber, WA | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Ullrich, RT; Wolf, J; Zander, T | 2 |
| Ashley, S; Chua, S; Cook, G; Coward, JI; Gunapala, R; Myerson, JS; O'Brien, ME; Popat, S; Puglisi, M; Sharma, B; Trani, L; Wotherspoon, A | 1 |
| Bengtsson, T; Hicks, RJ; Peterson, A; Port, RE | 1 |
| Collie-Duguid, ES; Law, AA; Smith, TA | 1 |
| Mason, DP | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Bokacheva, L; Carlin, S; Halliday, J; Kotedia, K; Koutcher, JA; Le, CH; Reese, M; Ricketts, SA | 1 |
| Boellaard, R; Dietlein, M; Holstein, A; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Scheffler, M; Wolf, J; Zander, T | 1 |
| Boellaard, R; Büttner, R; Dietlein, M; Engel-Riedel, W; Heukamp, L; Kahraman, D; Kobe, C; Lammertsma, AA; Neumaier, B; Nogova, L; Papachristou, I; Querings, S; Scheffler, M; Stoelben, E; Wolf, J; Zander, T | 1 |
| Carbonetti, G; Carlin, SD; Chiosis, G; de Stanchina, E; Divilov, V; Gomes-DaGama, EM; Holland, JP; Janjigian, YY; Lewis, JS; Viola-Villegas, N | 1 |
| Aktan, G; Baselga, J; Coccia-Portugal, MA; Cortés, M; Cure, H; de Azambuja, E; Di Cosimo, S; Eidtmann, H; Fauria, K; Flamen, P; Gámez, C; Garcia, C; Gebhart, G; Holmes, E; Kim, SB; Piccart, M; Robles, J; Van Dooren, V; Vuylsteke, P | 1 |
| Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y | 1 |
| Alfieri, RR; Ardizzoni, A; Bartolotti, M; Bordonaro, R; Bortesi, B; Bruzzi, P; Caffarra, C; Cavazzoni, A; Cosentino, S; Fumarola, C; Ippolito, M; Latteri, F; Petronini, PG; Ruffini, L; Scarlattei, M; Soto Parra, HJ; Spadaro, P; Tiseo, M | 1 |
| Amler, L; Eaton, K; Fine, BM; Gitlitz, B; Hicks, R; Hughes, B; Loecke, D; Mileshkin, L; Mitchell, P; Pirzkall, A; Townley, P; Wood, K | 1 |
| Couturier, O; Fosse, P; Hachemi, M; Hureaux, J; Lacœuille, F; Urban, T; Vervueren, L | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Barquin, E; Collins, B; Gardner, K; Judson, I; Jürgensmeier, JM; Leahy, M; Marotti, M; Scurr, M; Young, H | 1 |
| Aukema, TS; Burgers, SA; Klomp, HM; Rijna, H; Schaake, EE; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Aukema, TS; Burgers, SA; Codrington, HE; Klomp, HM; Rijna, H; Schaake, EE; Teertstra, HJ; Valdés Olmos, RA; van Gool, MH; van Pel, R; van Tinteren, H | 1 |
| Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS | 1 |
| Frechen, S; Fuhr, U; Kahraman, D; Kobe, C; Nogova, L; Scheffler, M; Suleiman, AA; Wolf, J; Zander, T | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN | 1 |
| Bassett, P; Chicklore, S; Chua, S; Cook, GJ; Goh, V; Loi, HY; O'Brien, ME; Punwani, R; Sharma, B; Siddique, M | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I | 1 |
| Guckenberger, M | 1 |
| Arteaga, CL; Barry, WT; Dees, EC; Falkson, CI; Guo, H; Hobday, TJ; Krop, IE; Lin, NU; Mayer, IA; Najita, JS; Nanda, R; Richardson, AL; Rimawi, MF; Ryabin, N; Van den Abbeele, AD; Winer, EP; Wolff, AC; Yap, JT | 1 |
| Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC | 1 |
| Buck, A; Bundschuh, R; Dandekar, G; Fecher, D; Hofmann, E; Lückerath, K; Nietzer, S; Steinke, M; Walles, H; Walles, T | 1 |
| Aboagye, EO; Beckley, A; Carroll, L; Kaliszczak, MA; Nguyen, QD; Pisaneschi, F; Slade, RL; Smith, G | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
2 review(s) available for fluorodeoxyglucose f18 and quinazolines
| Article | Year |
|---|---|
The role of surgery for locally advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Lymphatic Metastasis; Multimodal Imaging; Neoplasm Staging; Paclitaxel; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
25 trial(s) available for fluorodeoxyglucose f18 and quinazolines
| Article | Year |
|---|---|
Prospective study of positron emission tomography for evaluation of the activity of lapatinib, a dual inhibitor of the ErbB1 and ErbB2 tyrosine kinases, in patients with advanced tumors.
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Male; Middle Aged; Neoplasms; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Receptor, ErbB-2; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Is 18F-FDG PET/CT useful for the early prediction of histopathologic response to neoadjuvant erlotinib in patients with non-small cell lung cancer?
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Topics: Biological Transport; Blood Glucose; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Feasibility Studies; Fluorodeoxyglucose F18; Guideline Adherence; Humans; Internationality; Lung Neoplasms; Positron-Emission Tomography; Quality Control; Quinazolines; Treatment Outcome | 2011 |
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Survival Analysis; Thymidine | 2011 |
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines | 2011 |
(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Biological Transport; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Time Factors; Treatment Outcome | 2011 |
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Phenotype; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2012 |
18F-FDG PET as a surrogate biomarker in non-small cell lung cancer treated with erlotinib: newly identified lesions are more informative than standardized uptake value.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Likelihood Functions; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Time Factors | 2012 |
Response of HT29 colorectal xenograft model to cediranib assessed with 18 F-fluoromisonidazole positron emission tomography, dynamic contrast-enhanced and diffusion-weighted MRI.
Topics: Animals; Antineoplastic Agents; Contrast Media; Fluorodeoxyglucose F18; Gadolinium DTPA; HT29 Cells; Humans; Neoplasms, Experimental; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Tumor lesion glycolysis and tumor lesion proliferation for response prediction and prognostic differentiation in patients with advanced non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dideoxynucleosides; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Quinazolines; Treatment Outcome | 2012 |
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Time Factors; Tomography, X-Ray Computed; Trastuzumab; Treatment Outcome | 2013 |
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Multimodal Imaging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recurrence; Tomography, X-Ray Computed | 2014 |
[¹⁸F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiography; Radiopharmaceuticals; Survival Rate; Time Factors | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
Phase II study of cediranib in patients with advanced gastrointestinal stromal tumors or soft-tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Remission Induction; ROC Curve; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Modeling tumor dynamics and overall survival in advanced non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dideoxynucleosides; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Survival Analysis | 2015 |
[Oligoprogression].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Prospective Studies; Quinazolines; Radiosurgery; Radiotherapy Dosage; Retreatment; Survival Rate; Treatment Failure | 2015 |
Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography I
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Female; Fluorodeoxyglucose F18; Humans; Lapatinib; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2015 |
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
26 other study(ies) available for fluorodeoxyglucose f18 and quinazolines
| Article | Year |
|---|---|
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2008 |
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945.
Topics: Animals; Biomarkers, Tumor; Carrier Proteins; Chemistry, Pharmaceutical; Female; Fluorodeoxyglucose F18; Folate Receptor 1; Folate Receptors, GPI-Anchored; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Positron-Emission Tomography; Quinazolines; Receptors, Cell Surface; Thymidylate Synthase; Time Factors | 2008 |
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Preclinical and clinical evidence that Deoxy-2-[18F]fluoro-D-glucose positron emission tomography with computed tomography is a reliable tool for the detection of early molecular responses to erlotinib in head and neck cancer.
Topics: Aged; Animals; Blotting, Western; Cell Line, Tumor; Erlotinib Hydrochloride; Female; Fluorescent Antibody Technique; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT.
Topics: Amino Acid Substitution; Animals; Binding, Competitive; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Imaging; Mutant Proteins; Mutation; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2011 |
Metabolic imaging allows early prediction of response to vandetanib.
Topics: Aged; Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Dihydroxyphenylalanine; Down-Regulation; Female; Fluorodeoxyglucose F18; G1 Phase; Glucose; Humans; Male; Mice; Mice, SCID; Microarray Analysis; Piperidines; Positron-Emission Tomography; Proto-Oncogene Proteins c-ret; Quality Control; Quinazolines; Radiopharmaceuticals; Resting Phase, Cell Cycle; RNA, Neoplasm; Signal Transduction; Thymidine; Thyroid Neoplasms; Tomography, Emission-Computed | 2011 |
Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Dideoxynucleosides; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Fluorouracil; HCT116 Cells; Humans; Immunoblotting; Ki-67 Antigen; Methotrexate; Mice; Mice, Nude; Organophosphates; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Thymidine; Thymidine Kinase; Xenograft Model Antitumor Assays | 2011 |
Prediction of response to targeted therapies in lung cancer using dynamic imaging: still far from clinical implementation.
Topics: Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Positron-Emission Tomography; Quinazolines | 2011 |
Osteoblastic healing response: discordant PET/CT findings.
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Multimodal Imaging; Osteoblasts; Positron-Emission Tomography; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Predictive value of early and late residual 18F-fluorodeoxyglucose and 18F-fluorothymidine uptake using different SUV measurements in patients with non-small-cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Dideoxynucleosides; Discriminant Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Radiopharmaceuticals; Retrospective Studies; ROC Curve | 2012 |
Influence of resistance to 5-fluorouracil and tomudex on [18F]‑FDG incorporation, glucose transport and hexokinase activity.
Topics: 3-O-Methylglucose; Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Fluorouracil; Glucose; Hexokinase; Humans; Quinazolines; Radiopharmaceuticals; Thiophenes | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
Topics: Afatinib; Animals; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Humans; Mice; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Radiochemistry; Receptor, ErbB-2; Stomach Neoplasms; Treatment Outcome | 2013 |
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Non-Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of (18)F-FDG Uptake at PET-Association with Treatment Response and Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2015 |
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2015 |
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate | 2015 |
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Organ Culture Techniques; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Rats, Inbred Lew | 2016 |
Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography.
Topics: ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Contrast Media; Drug Resistance, Neoplasm; ErbB Receptors; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Positron-Emission Tomography; Quinazolines; Substrate Specificity | 2016 |